Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Compugen Establishes SAB to Guide Pipeline Program Development

Published: Tuesday, August 27, 2013
Last Updated: Tuesday, August 27, 2013
Bookmark and Share
Key opinion leaders to advise Company on research and development involving therapeutic product candidates in the fields of immunology and oncology.

Compugen Ltd. has announced the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company’s activities in the fields of immunology and oncology, including its early stage pipeline of therapeutic proteins and monoclonal antibodies.

The members of Compugen's SAB include four renowned translational scientists and clinicians in oncology and immunology.

Listed in alphabetical order, the members are: Charles G. Drake, MD, PhD, Associate Professor of Oncology, Immunology and Urology at Johns Hopkins Kimmel Cancer Center; Iain B. McInnes, MD, PhD, Director of the Institute of Infection, Immunity, and Inflammation at the University of Glasgow; Antoni Ribas, MD, PhD, Professor at the Department of Medicine, Hematology/Oncology, University of California Los Angeles; and Howard R. Soule, PhD, Executive Vice President and Chief Science Officer, Prostate Cancer Foundation.

Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, “We are delighted to welcome this prestigious group of scientists to our Scientific Advisory Board for oncology and immunology, two therapeutic fields with substantial unmet medical needs and the primary fields of focus for Compugen. We very much appreciate their willingness and enthusiasm to collaborate with us as members of our SAB, which we view as further recognition of our growing presence in these important therapeutic areas.”

Dr. Cohen-Dayag continued, “Recently we announced the signing of our first agreement covering product candidates identified in our initial focused discovery program based on our unique predictive discovery infrastructure. This specific discovery effort was focused on immune checkpoint proteins, and this first agreement, with Bayer HealthCare, covered the development and commercialization of antibody therapeutics against two novel oncology targets for cancer immunotherapy.”

Dr. Cohen-Dayag concluded, “We are confident that the knowledge and experience of our newly formed SAB, which includes well-recognized world experts in the field of immune checkpoint proteins, will prove invaluable as we continue our development and commercialization efforts for our current product candidates, undertake additional focused discovery programs, and further enhance our predictive discovery infrastructure through deeper insights into the underlying science.”

Compugen’s Scientific Advisory Board Members:

Charles G. Drake, MD, PhD
Dr. Drake specializes in cancer immunotherapies, focusing on immune checkpoints, and cancer vaccines. He has significant experience conducting clinical trials involving these therapies. He is Co-Director of the Multi-disciplinary Prostate Cancer Clinic at Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, and is an Associate Professor, Medical Oncology, Immunology, and Urology. Dr. Drake is also a member of the Prostate Cancer Foundation Scientific Advisory Board. Dr. Drake received his PhD in Immunology from the National Jewish Center for Immunology and his MD from the University of Colorado Health Sciences Center in Denver, Colorado.

Iain B. McInnes, FRCP, PhD
Prof. McInnes’ major area of interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He is Muirhead Chair of Medicine and Director of Institute of Infection, Immunity and Inflammation at the University of Glasgow. He oversees a translational science program and is involved with an extensive clinical trials facility performing studies of novel biologic agents in inflammatory arthritis. He has served as Principal Investigator for numerous clinical studies in drug development programs. Prof. McInnes studied medicine at the University of Glasgow, and trained in PhD and postdoctoral studies at the National Institutes of Health in Bethesda, Maryland.

Antoni Ribas, MD, PhD
Prof. Ribas holds positions in Hematology/Oncology and Surgical Oncology at the University of California, Los Angeles (UCLA). He conducts laboratory and clinical research on novel strategies for immunotherapy of cancer, focusing on malignant melanoma, and has served as Principal Investigator for clinical studies in drug development programs. He is the Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG (Southwest Oncology Group). Prof. Ribas is also a permanent committee member of the National Cancer Institute (NCI) grant review panels and an elected member of the American Society of Clinical Investigation (ASCI). He studied medicine at the University of Barcelona, Spain, and has undergone postdoctoral training at the Sidney Kimmel Cancer Center in San Diego and at UCLA.

Howard R. Soule, PhD
Dr. Soule is a world leader in the identification and development of new drugs for prostate cancer. Dr. Soule is the Executive Vice President and Chief Science Officer at the Prostate Cancer Foundation, and Senior Fellow at the Milken Institute. He coordinates global academic, government and biopharmaceutical sector research activity and is responsible for the implementation of Prostate Cancer Foundation global research strategies. Dr. Soule received his PhD from Baylor College of Medicine in virology and epidemiology, and was a postdoctoral fellow in immunology and vascular biology at the Scripps Research Institute. Dr. Soule has substantial R&D and business development experience in the biopharmaceutical and diagnostics industries.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Reports Fourth Quarter and Calendar 2013 Results
Company discloses key 2014 corporate objectives.
Wednesday, February 12, 2014
Compugen Announces Addition of Prof. Drew Pardoll to its SAB
Prof. Pardoll is a world leader in immuno-oncology research and in the development of novel cancer therapeutics.
Wednesday, January 22, 2014
Compugen Announces $15 Million Funding Agreement for its Keddem Subsidiary
Keddem's unique technology platform focuses on small molecule drug discovery.
Thursday, March 21, 2013
Compugen Announces Initial Validation Results for Two Novel Immunomodulatory Proteins
CGEN-15031 and CGEN-15051 demonstrate therapeutic potential in animal models of autoimmune diseases.
Tuesday, July 24, 2012
Compugen Reports First Quarter 2012 Financial Results
Non-cash Baize arrangements charges added significantly to loss for quarter.
Monday, May 07, 2012
Compugen Reports Fourth Quarter and Calendar 2011 Financial Results Feb 07, 2012
Immunomodulatory therapeutics program being extended beyond B7/CD28 family.
Thursday, February 09, 2012
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Findings support CGEN-15001T's potential as a powerful drug target for cancer immunotherapy.
Monday, February 06, 2012
Compugen to Broaden and Accelerate mAb Program for Oncology and Immunology
$8 million towards expanded program will be provided by Baize Investments via second research funding agreement with Compugen.
Thursday, December 22, 2011
Scientific News
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos